Medical management of hypertension.
In a paper like this, with such diverse information, it is impossible to summarize the content completely. Suffice it to say that a stepwise approach to the management of essential hypertension has been presented, beginning with a diuretic agent as the cornerstone of management for most patients. Recommendations for the addition of a second, third, or even a fourth agent have been offered based on a discussion of the site of action of various therapeutic agents. The common side effects and toxicity of various drugs have also been discussed. It cannot be overemphasized that the physician's knowledge of his patient and a thorough understanding of drug actions, interactions, and reactions are mandatory if highly effective, individualized therapeutic programs are to be implemented. Likewise, educating the patient about his disease and eliciting his maximal cooperation are keys to therapeutic success.
D001581:Benzothiadiazines; D004232:Diuretics; D006145:Guanethidine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use; D012110:Reserpine / Q000009:adverse effects / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D014223:Triamterene / Q000009:adverse effects / Q000627:therapeutic use
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D008750:Methyldopa; D012110:Reserpine; D014223:Triamterene; D006145:Guanethidine